- New Antiviral Therapies for Hepatitis C
-
O'Leary J, Chung RT
- KMID: 1085299
- Korean J Hepatol.
- 2003 Dec;9(4):265-274.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients
-
Lee YJ
- KMID: 1073296
- Korean J Hepatol.
- 2008 Dec;14(4):443-445.
- doi: 10.3350/kjhep.2008.14.4.443
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Emerging Therapies for Hepatitis C
-
Kim DY, Ahn SH, Han KH
- KMID: 2070056
- Gut Liver.
- 2014 Sep;8(5):471-479.
- doi: 10.5009/gnl14083
The combination of pegylated interferon (PEG-IFN) and ribavirin (RBV), the current therapy for hepatitis C virus (HCV) infection, has saved the lives of many HCV-infected patients. Direct-acting antivirals (DAAs) target... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
-
Toshikuni
- KMID: 2412206
- Gut Liver.
- 2017 May;11(3):335-348.
- doi: 10.5009/gnl15458
Chronic hepatitis C virus (HCV) infection may eventually lead to liver cirrhosis (LC), a condition associated with a high risk of liver failure and hepatocellular carcinoma. Although interferon (IFN)-based therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation
-
Kim BK, Kwon SY, Ko SY, Choe WH, Lee CH, Han HS, Chang SH
- KMID: 1073304
- Korean J Hepatol.
- 2008 Dec;14(4):519-524.
- doi: 10.3350/kjhep.2008.14.4.519
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was... -
- CITED
-
- Close
- SHARE
-
- Close
- Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization
-
Sung PS, Bae SH, Jang JW, Song DS, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK
- KMID: 1792608
- Korean J Hepatol.
- 2011 Dec;17(4):299-306.
- doi: 10.3350/kjhep.2011.17.4.299
BACKGROUND/AIMS: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection
-
Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, Park ET, Lee YJ, Lee SH, Seol SY
- KMID: 1381462
- Korean J Hepatol.
- 2008 Sep;14(3):318-330.
- doi: 10.3350/kjhep.2008.14.3.318
BACKGROUND/AIMS: We assessed the efficacy and safety of pegylated interferon (peginterferon) plus ribavirin and identified the predictors of a sustained virologic response (SVR) in Korean patients with chronic hepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
- Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
-
Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH
- KMID: 2412235
- Gut Liver.
- 2017 Jul;11(4):543-550.
- doi: 10.5009/gnl16530
BACKGROUND/AIMS: To evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection. We aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study
-
Kim JI, Kim SH, Lee BS, Lee HY, Lee TH, Kang YW, Lee HI, Kim AN, Nam SW, Park BC, Chae HB, Kim SB, Song IH, Park JY, Kim HS
- KMID: 1073301
- Korean J Hepatol.
- 2008 Dec;14(4):493-502.
- doi: 10.3350/kjhep.2008.14.4.493
BACKGROUNDS/AIMS: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of... -
- CITED
-
- Close
- SHARE
-
- Close
- A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
-
You BC, Kim YS, Kim HI, Kim SH, Park SS, Seo YR, Kim SG, Lee SW, Kim HS, Jeong SW, Jang JY, Kim BS
- KMID: 1392906
- Clin Mol Hepatol.
- 2012 Sep;18(3):272-278.
- doi: 10.3350/cmh.2012.18.3.272
BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN alpha-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose... -
- CITED
-
- Close
- SHARE
-
- Close
- Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon alpha Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
-
Ali FT, Ali MA, Elgizawy M, Elsawy AM
- KMID: 2160636
- Gut Liver.
- 2015 Jul;9(4):516-524.
- doi: 10.5009/gnl14162
BACKGROUND/AIMS: The T-helper 1 (TH1) immune reaction is essential for the eradication of hepatitis C virus (HCV) during pegylated interferon alpha (PEG-IFN-alpha)- and ribavirin (RBV)-based therapy in chronic HCV patients.... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
-
Jung CH, Um SH, Kim TH, Yim SY, Suh SJ, Yim HJ, Seo YS, Choi HS, Chun HJ
- KMID: 2412080
- Gut Liver.
- 2016 Sep;10(5):808-817.
- doi: 10.5009/gnl15360
BACKGROUND/AIMS: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index
-
Lee K, Sinn DH, Gwak GY, Cho HC, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW
- KMID: 2412078
- Gut Liver.
- 2016 Sep;10(5):796-802.
- doi: 10.5009/gnl15368
BACKGROUND/AIMS: Following sustained virological response (SVR) for chronic hepatitis C (CHC) infection, patients with advanced fibrosis require regular monitoring for hepatocellular carcinoma (HCC). The aspartate aminotransferase to platelet ratio index... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis
-
Park JI, Choi KM, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, Chung YH, Lee YS, Suh DJ
- KMID: 1776830
- Korean J Hepatol.
- 2007 Dec;13(4):543-555.
- doi: 10.3350/kjhep.2007.13.4.543
BACKGROUND AND AIMS: Hepatitis C virus (HCV)-associated cirrhosis is an increasingly frequent indication for liver transplantation (LT). However, HCV recurrence is universal and this immediately occurs following LT, which... -
- CITED
-
- Close
- SHARE
-
- Close
